About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

Not Yet RecruitingNCT06963632

A Real-world Study on Golidocitinib-based Therapeutic Regimens for the Treatment of Patients With Peripheral T-cell Lymphoma

This real-world study aims to evaluate the safety and efficacy of golidocitinib-based treatment regimens in patients with peripheral T-cell lymphoma (PTCL), without intervention in the selection of th...

Lead sponsor: Ruijin Hospital•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Clareo turns complex medical information into clear understanding you can use.

Bring this clarity to your next appointment.

Keep all your medical notes and next steps in one place.

Start Free Trial

Contacts

Weili Zhao

CONTACT

+86 02164370045 zwl_trial@163.com

Sponsors

Lead Sponsor

Ruijin Hospital

Age

18 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•1. Voluntarily sign and acknowledge understanding of the Informed Consent Form
•2. Clinically confirmed diagnosis of peripheral T-cell lymphoma
•3. Inclusion of PTCL patients who initiated a Golidocitinib-based treatment regimen within the past 3 months
•4. Compliance with clinical management and provision of disease-related historical medical information required for the study, including but not limited to medical records, treatment history, and prior/prescribed therapeutic regimens

Exclusion Criteria

•1. Poor patient adherence
•2. Investigator-deemed ineligibility for enrollment

Related studies

Active Not RecruitingPhase 1

A Clinical Trial of BP1002 in Patients With Advanced Lymphoid Malignancies

NCT04072458 · Mantle Cell Lymphoma, Peripheral T-cell Lymphoma (PTCL), and more

COMPLETEDPhase 1

Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors

NCT05225584 · Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL), and more

TERMINATEDPhase 2

Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma

NCT02314247 · Peripheral T-cell Lymphoma (PTCL), Cutaneous T-cell Lymphoma (CTCL)

COMPLETEDPhase 1

Subcutaneous Recombinant Human IL-15 (s.c. rhIL-15) and Alemtuzumab for People With Refractory or Relapsed Chronic and Acute Adult T-cell Leukemia (ATL)

NCT02689453 · T-Cell Lymphoma Relapsed, Adult T-Cell Leukemia (ATL), and more

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: May 9, 2025Terms

Trial snapshot

StatusNOT_YET_RECRUITING

Phase—

Enrollment1,000

Start dateApr 2025

Last updatedMay 9, 2025

Condition

Peripheral T-cell Lymphoma (PTCL)

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: May 9, 2025Data synced to Clareo: May 10, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions